🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the fight against increasingly resistant strains of the bacteria, according to health experts.

An International Health Concern

Cases of gonorrhoea are escalating globally, with estimates suggesting in excess of 82 million infections each year. Notably increased rates are seen in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the context of rising global incidence, escalating drug resistance and the very limited available drugs currently available.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the drug firm Innoviva to develop it.

“This authorization signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Data and Global Access

As per data published in a prominent scientific publication, zoliflodacin eradicated over nine in ten of cases of the STI. This establishes an equal footing with the current standard treatment, which uses a dual-drug approach. The study enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in many developing nations.

Doctors on the front lines have voiced optimism. The availability of a easy-to-administer therapy like this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as vital to lessen the impact of the illness for people and to halt the transmission of extremely resistant gonorrhoea worldwide.